{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:36Z","timestamp":1786997916379,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.urology.2010.05.026","type":"journal-article","created":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T04:21:24Z","timestamp":1288930884000},"page":"1175-1181","source":"Crossref","is-referenced-by-count":60,"title":["Zoledronic Acid Improves Clinical Outcomes When Administered Before Onset of Bone Pain in Patients With Prostate Cancer"],"prefix":"10.1016","volume":"76","author":[{"given":"Fred","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Eastham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2010.05.026_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2010.05.026_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urology.2010.05.026_bib3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2010.05.026_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2010.05.026_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2010.05.026_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2010.05.026_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ctrv.2007.10.002","article-title":"New research findings on zoledronic acid: survival, pain, and anti-tumour effects","volume":"34","author":"Saad","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urology.2010.05.026_bib9","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2010.05.026_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","article-title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer","volume":"4","author":"Saad","year":"2005","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.urology.2010.05.026_bib11","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.urology.2010.05.026_bib12","first-page":"24","article-title":"Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status (abstract)","author":"Barghout","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2010.05.026_bib13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2010.05.026_bib14","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2010.05.026_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.urology.2010.05.026_bib16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","article-title":"Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer","volume":"17","author":"Weinfurt","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2010.05.026_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/030089169808400403","article-title":"Role of pamidronate disodium in the treatment of metastatic bone disease","volume":"84","author":"Ripamonti","year":"1998","journal-title":"Tumori"},{"key":"10.1016\/j.urology.2010.05.026_bib18","first-page":"23","article-title":"Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: a survival-adjusted cumulative incidence analysis (abstract)","author":"Major","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.urology.2010.05.026_bib19","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2010.05.026_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.urology.2010.05.026_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006250","article-title":"Bisphosphonates for advanced prostate cancer","author":"Yuen","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urology.2010.05.026_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/14740338.6.3.305","article-title":"The safety of zoledronic acid","volume":"6","author":"Lipton","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.urology.2010.05.026_bib23","series-title":"Zometa\u00ae (zoledronic acid) [summary of product characteristics]","year":"2003"},{"key":"10.1016\/j.urology.2010.05.026_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07357900500449652","article-title":"The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer","volume":"24","author":"Van Poznak","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.urology.2010.05.026_bib25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.urology.2010.05.026_bib26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","article-title":"Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy","volume":"13","author":"Estilo","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.urology.2010.05.026_bib27","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","article-title":"Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations","volume":"137","year":"2006","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.urology.2010.05.026_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2010.05.026_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2010.05.026_bib30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.urology.2010.05.026_bib31","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","article-title":"Cancer treatment-induced bone loss in breast and prostate cancer","volume":"26","author":"Saad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2010.05.026_bib32","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429510007326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429510007326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T22:51:20Z","timestamp":1559775080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429510007326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0090429510007326"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2010.05.026","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}